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 1. ABSTRACT 
 
 
Reelin is a conserved extracellular glycoprotein crucial for neurodevelopment. In adulthood, 
Reelin is an important modulator of NMDA receptor-mediated neurotransmission, required 
for synaptic plasticity, learning and memory. Consequently, abnormal Reelin-mediated 
signaling has been associated with many human brain disorders involving directly or 
indirectly altered NMDA receptor function. For most neurological and neuropsychiatric 
disorders, abnormalities during brain development appear central in the disease etiology. 
However, a similar causative relationship for neurodegenerative diseases, like Alzheimer’s 
disease (AD), has not been investigated yet. 
 The findings reviewed here center around the hypothesis that dysfunctional Reelin-
mediated signaling converges overlapping molecular pathogenic pathways in schizophrenia 
and AD; highlighting a surprising interaction between prenatal inflammation and 
developmental abnormalities that appear to play a common role in aging-related 
neuropathology and cognitive decline. I hypothesize that the progression from normal aging 
to AD possibly results from late-gestational misregulations of inflammatory cytokines, 
resulting in immediate neuronal loss of Reelin-expressing neurons, facilitation of protein 
aggregation and concomitant impairments in proteolytical degradation during adulthood and 
aging, accompanied by chronic inflammation, expected to induce neurodegenerative 
processes. Conversely, a developmental immune challenge during mid-gestation, shown to 
preferentially mimic schizophrenia-like behavioural and neurochemical abnormalities, 
including impaired Reelin-mediated signaling, prevents progressive neurodegeneration, 
potentially linked to the immature embryonic immune system at the time of insult, which 
occludes long-term changes and sub-chronic elevations of inflammatory cytokines. Thus, the 
findings presented in this review suggest that schizophrenia can indeed be described as a form 
of accelerated aging or “dementia praecox” as first described by Emil Kraepelin in 1906. 
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 2. The Reelin signaling pathway in the developing  
and adult brain 
 
 
Reelin is a highly conserved glycoprotein that controls several essential steps during the 
embryonic phase of brain development. It is synthesized and secreted from Cajal-Retzius 
(CR) cells in the marginal zone and required for the splitting of the preplate and the correct 
formation and positioning of the neuronal cell layers in the cortical plate (Rakic and Caviness, 
1995; Del Rio et al., 1997; Curran and D'Arcangelo, 1998; Frotscher, 1998; Rice and Curran, 
2001; Tissir and Goffinet, 2003; Frotscher et al., 2007; Cooper, 2008). It is also necessary for 
the migration and positioning of the Purkinje cells which is a prerequisite for the expansion of 
the migrating granule cells in the developing cerebellum (Mariani et al., 1977). The reeler 
mouse, a naturally occurring mutant which is deficient in Reelin (Falconer, 1951), shows a 
severe perturbation of the characteristic inside-out layering of the cortex, the lamination of the 
hippocampus, and has a very small and non-foliated cerebellum (Hamburgh, 1963). 
Phenotypically, the autosomal recessive mutation leads to the characteristic uncoordinated 
and unsteady gait, temors, severe ataxia and usually early death around the time of weaning 
(Falconer, 1951). The discovery and description of several other spontaneous or transgenic 
mutations resulting in Reeler-like phenotypes have been essential for the identification of the 
members of the Reelin signaling cascade and for our understanding of the molecular pathways 
through which Reelin controls neuronal functions during both development and adulthood.  
 
The reelin gene, its product and the downstream signaling cascade. In 1995, two groups 
independently cloned the reelin gene. Tom Curran’s team isolated the gene using the rltg allele 
produced by transgenic insertion as a probe (D'Arcangelo et al., 1995). At the same time, 
Hirotsune and colleagues isolated the cDNA for the mouse reelin gene using a positional 
cloning approach (Hirotsune et al., 1995). The gene contains 65 exons spanning 
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approximately 450 kb of genomic DNA. The genomic structures of the mouse and human 
reelin genes appear to be highly conserved. In mice, the reeler gene is located on 
chromosome 5, in humans the gene has been mapped to chromosome 7q22 (DeSilva et al., 
1997; Royaux et al., 1997). The proximal 5’ upstream sequence of the reelin gene contains 
two transcription start sites embedded within a CpG island (Royaux et al., 1997). This 
promoter region contains recognition sites for the transcription factors Pax6, Tbr1, Sp1, as 
well as CREB and NF-κB, involved in transducing cytoplasmic signals to the nucleus 
(Royaux et al., 1997; Grayson et al., 2005) and implicated in regulating reelin expression in 
the developing brain. In addition to the transcription factor-mediated gene regulation, 
epigenetic modulations including acetylation of histones and methylation of cytosine play 
significant roles in the regulation of the reelin gene. Chromatin immunoprecipitation assays 
demonstrated that the activation of the reelin gene involves the dissociation of the DNA 
(cyosine-5) methyltransferase 1 (DNMT1) and the chromatin remodeling enzyme methyl-
CpG binding protein 2 (MeCP2) from the promoter, resulting in an increased acetylation of 
histones H3 in the region (Kundakovic et al., 2007). 
The 10,383-bp reelin open reading frame encodes a 12 kb mRNA which is translated 
into a 3,461 amino acid (aa) protein with a relative molecular mass of about 450 kDa (Figure 
1). The N-terminus is glycosylated and shares 25% identity with that of F-spondin. The 
central sequence consists of eight “Reelin repeats” each of which is composed of 350-390 aa 
and contains an EGF-like motif in the center. This is followed by a highly charged C-terminus 
(D'Arcangelo et al., 1995). A deletion in this region, as detected in reeler Orleans (rlOrl) mice 
(de Bergeyck et al., 1997; Derer et al., 2001), results in protein misfolding which prevents the 
secretion of the truncated protein (Derer et al., 2001; Nakano et al., 2007). Recent evidence 
suggest also an involvement of the C-terminus in the activation of downstream signaling 
events, potentially mediated by a co-receptor (Nakano et al., 2007). Reelin is processed 
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proteolytically at two sites to produce a total of five different fragments. While a zinc-
dependent metalloproteinase of the astacin/adamalysin family cuts at the N-terminal cleavage 
site (Lambert de Rouvroit et al., 1999),  the identity of C-terminal cleaving protease is 
currently unknown (Figure 1). The physiological functions of these individual Reelin 
fragments are not completely understood. It has been shown, however, that blocking of the N-
terminus with the CR-50 anti-Reelin antibody has neutralizing activity both in vitro and in 
vivo (Ogawa et al., 1995; Del Rio et al., 1997; Miyata et al., 1997; Nakajima et al., 1997). In 
addition, work from Andre Goffinet’s group provided evidence that the central fragment is 
required and sufficient for normal cortical development in cultured embryonic brain slices 
(Jossin et al., 2007).  
Cell adhesion assays have shown that secreted Reelin can form large homomeric 
protein complexes via the CR-50 epitope in the N-terminal domain: while full-length Reelin 
forms disulfide-linked dimers, N-terminally truncated Reelin forms larger oligomeric 
complexes (Utsunomiya-Tate et al., 2000; Kubo et al., 2002), suggesting that the proteolytic 
processing may affect the tertiary structure required for the proper and stable 
assembly/dimerization or oligomerization of this protein. It has been proposed that the 
multimerization of Reelin is necessary for the clustering and activation of the different Reelin 
receptors, including the very low density lipoprotein receptor (VLDLR) and the 
apolipoprotein E receptor 2 (ApoER2, D'Arcangelo et al., 1999; Hiesberger et al., 1999; 
Utsunomiya-Tate et al., 2000; Strasser et al., 2004). Other potential Reelin receptors are the 
Cadherin-related neuronal receptor (CNR) family members (Senzaki et al., 1999) and Integrin 
α3β1 (Dulabon et al., 2000; Dong et al., 2003). However, binding of Reelin to CNR1 has not 
been seen by (Jossin et al., 2004) and recent evidence demonstrated that α3β1 Integrins in 
migrating neurons are not essential for glial-guided migration and Reelin signaling 
(Belvindrah et al., 2007). Only VLDLR and ApoER2 double-mutant mice show a reeler 
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phenotype (Trommsdorff et al., 1999), suggesting that indeed Reelin acts primarily on the two 
lipoprotein receptors in vivo (Hack et al., 2007). 
Independent studies from several groups deciphered through genetic and biochemical 
approaches the members of the signaling pathway involved in relaying Reelin-receptor 
binding to downstream alterations of the actin cytoskeleton and microtubule dynamics which 
is required for directional migration (Figure 2). Binding of multimeric Reelin to VLDLR and 
ApoER2 induces their clustering and phosphorylation of the cytoplasmic adapter protein 
disabled 1 (Dab1) by the Src family tyrosine (SFKs) kinases Fyn and Src (Howell et al., 1999; 
Arnaud et al., 2003b; Bock and Herz, 2003; Jossin et al., 2003; Kuo et al., 2005). Dab1 is 
initially phosphorylated on two tyrosine sites (Y185, Y198) which seem to be required to 
permit transphosphorylation of adjacent Dab1 molecules at all 4 tyrosine sites (Y185, Y198, 
Y220, Y232) (Feng and Cooper, 2009). This leads to the recruitment and activation of 
additional activated non-receptor tyrosine kinases allowing the activation of a cytosolic kinase 
cascade, beginning with Phosphatidylinositol-3-kinase (PI3K), Akt/PKB and mTor, and 
ending with the inhibition of Glycogen synthase kinase 3β (GSK3β), one of the main kinases 
that phosphorylates the microtubule-stabilizing protein Tau (D'Arcangelo et al., 1999; 
Hiesberger et al., 1999; Beffert et al., 2002; Ballif et al., 2003; Bock et al., 2003). While 
phosphorylated Dab1(Y185,Y198) preferentially activates the PI3-kinase/Akt pathway, 
phospho-Dab1(Y220,Y232) recruits Crk/CrkL-C3G complexes which in turn stimulate Rap1 
(Ballif et al., 2004; Chen et al., 2004; Huang et al., 2004; Feng and Cooper, 2009). 
Phosphorylation of Dab1 leads also to the recruitment of Nckβ and lissencephaly 1 (LIS1), 
additional proteins involved in regulating the actin cytoskeleton and microtubule dynamics, 
respectively (Assadi et al., 2003; Pramatarova et al., 2003; Shu et al., 2004) and participating 
in the regulation of neuronal migration and cortical lamination. Recently, Michael Frotscher’s 
group showed that the regulation of the actin cytoskeleton through the Reelin signaling 
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cascade also involves activation of LIM1 kinase which results in increased n-cofilin 
phosphorylation in the leading processes of migrating neurons approaching the marginal zone 
(Chai et al., 2009; Frotscher et al., 2009). These novel findings provide first evidence that 
Reelin-mediated signaling result in the stabilization of the actin cytoskeleton, allowing cell 
anchoring and termination of migration. Finally, recruitment of ubiquitin ligases to 
phosphorylated Dab1 results in ubiquitination of the protein, likely mediating the 
phosphorylation-dependent endocytosis of the entire Reelin signaling complex. With Reelin 
being targeted to the lysosome and Dab1 being degraded by the proteasome, the signal is 
terminated and the receptors recycle back to the membrane (Arnaud et al., 2003a; Bock et al., 
2004; Suetsugu et al., 2004; Morimura et al., 2005; Kerjan and Gleeson, 2007). 
  
The Reelin pathway in adult synaptic plasticity. The expression pattern of Reelin changes 
after the end of the neuronal migration phase. The former marginal zones of the developing 
cortex are defined in the adult brain as layer I of the neocortex and stratum lacunosum-
moleculare and outer molecular layer of the DG in the hippocampus (Frotscher, 1998). A 
small number of Cajal-Retzius cells are still found in these layers. Reelin in the adult brain is 
maintained by GABAergic interneurons throughout the neocortex and hippocampus, and 
glutamatergic mitral cells in the olfactory bulb, granule cells in the cerebellum, and layer II 
pyramidal cells in the piriform and entorhinal cortex (Alcantara et al., 1998; Pesold et al., 
1998; Lacor et al., 2000; Abraham and Meyer, 2003; Pappas et al., 2003; Abraham et al., 
2004; Baloyannis, 2005; Miettinen et al., 2005; Herz and Chen, 2006; Ramos-Moreno et al., 
2006; Chin et al., 2007; Knuesel et al., 2009). 
Although this shift in expression may suggest novel, non-developmental functions of 
Reelin in the adult brain, the control of the actin cytoskeleton and microtubule dynamics, as 
well as the synapse and spine formation through this signaling cascade points to the 
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convergence of developmental processes and adult synaptic functions during learning and 
memory processes. Indeed, the expression of ApoER2, VLDLR and Dab1 continues unabated 
in the adult brain (Deguchi et al., 2003) and recent studies of the groups of Joachim Herz and 
Edwin Weeber provided evidence of a significant contribution of the Reelin signaling 
pathway to synaptic plasticity (Weeber et al., 2002; Beffert et al., 2005; Chen et al., 2005; 
Herz and Chen, 2006; Qiu et al., 2006c; Qiu et al., 2006b). Using ApoER2 and VLDLR 
deficient mice, they demonstrated that while baseline synaptic transmission was unaffected, 
high frequency stimulation reduced LTP induction in vldlr-knockout mice and a pronounced 
decay of late-phase LTP in apoer2-null mice (Weeber et al., 2002). This is in line with the 
hypomorphic phenotype of the single mutants with developmental defects affecting mainly 
hippocampus and neocortex (apoer2) or cerebellum (vldlr), and the reeler phenotype in 
double-mutants (Trommsdorff et al., 1999). In addition, exposure of wild-type hippocampal 
slices with Reelin significantly enhanced LTP in hippocampal slices of wild-type mice but not 
in vldlr- or apoer2 knockout mice (Weeber et al., 2002). Electrophysiological recordings in 
the CA1 of heterozygous reeler mice revealed significant reductions in excitatory 
postsynaptic potentials and paired pulse facilitation, as well as impaired LTD and LTP (Qiu et 
al., 2006c). A marked reduction in the frequency of spontaneous inhibitory postsynaptic 
currents was also observed, pointing to reduced inhibitory presynaptic inputs and impaired 
hippocampal plasticity in the absence of Reelin. Chen and colleagues further showed that 
Reelin through Src/Fyn and Dab1 mediates tyrosine phosphorylation of the NR2A and NR2B 
subunit of the NMDA receptor and potentiates calcium influx in primary wild-type but not 
Dab1 knockout neurons or in cells in which Reelin binding to its receptors is blocked by a 
receptor antagonist (Chen et al., 2005). Reelin-induced augmentation of Ca2+ entry through 
NMDA receptors did also increase phosphorylation and nuclear translocation of the 
transcription factor cAMP-response element binding protein (CREB), indicating that Reelin 
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may physiologically modulate learning and memory by modulating NMDA receptor functions 
(Figure 3). 
Further insights into the molecular mechanisms by which Reelin modulates synaptic 
plasticity and learning and memory through the ApoER2 receptors have been provided by the 
investigations of knock-in mice with either mutations of the Dab1 binding site, constitutive 
expression or complete absence of the alternatively spliced exon 19 (Beffert et al., 2005; 
Beffert et al., 2006). This exon encodes the binding site that mediates the interaction of 
ApoER2 with PSD-95, and with JNK-interacting proteins 1 and 2 (JIP), involved in the 
assembly of a kinase activating complex at the cytoplasmic domain of ApoER2 (Gotthardt et 
al., 2000; Stockinger et al., 2000). Biochemical, neuroanatomical, behavioural, and 
electrophysiological analysis of these mutant mice revealed that both the Dab1 binding site 
and exon 19 are necessary for the Reelin-mediated increase of synaptic plasticity to allow the 
coupling of ApoER2 and the activated Dab1–Src/Fyn complex to the NR2A and NR2B 
subunit of the NMDA receptor for its subsequent tyrosine phosphorylation and Ca2+ entry in 
the postsynaptic density (PSD, Beffert et al., 2005). The formation of this functional unit 
between ApoER2 and NMDA receptors is further ensured through extracellular interactions 
(Hoe et al., 2006b), suggesting a tight link between these two receptor systems. In addition, 
application of exogenous Reelin to adult hippocampal slices can modulate AMPA receptor-
mediated responses. This was, however, only detected after longer Reelin exposure (>20 min) 
and was not secondary to enhanced NMDA receptor function but associated with an increased 
receptor number in the PSD (Qiu et al., 2006b). Further evidence for a critical role of the 
Reelin signaling cascade in controlling synaptic strength and plasticity has been provided by 
the observations that Reelin treatment not only increased spontaneous and evoked AMPA 
receptor currents, but also reduced the number of silent synapses, facilitated the 
developmental switch from NR2B to NR2A and enhanced the surface expression of AMPA 
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receptors in the CA1 (Qiu and Weeber, 2007). These data complement previous findings 
obtained from cultured hippocampal neurons that revealed the dependence of the somatic 
NMDA receptor composition, trafficking, assembly, and maintenance on Reelin-mediated 
signaling (Sinagra et al., 2005; Groc et al., 2007; Campo et al., 2009). They also fit with in 
situ observations where neurons exhibit reduced axonal (Del Rio et al., 1997; Borrell et al., 
1999) and dendritic branching, as well as stunted dendritic growth and significantly fewer 
spines in the complete or partial absence of Reelin or its receptors (Trommsdorff et al., 1999; 
Niu et al., 2004; Borrell et al., 2007; Qiu and Weeber, 2007; Niu et al., 2008). This likely 
underlies the impaired performance of heterozygous reeler mice in certain learning and 
memory tasks as compared to wild type controls (Tueting et al., 1999; Krueger et al., 2006; 
Qiu et al., 2006c; Qiu et al., 2006a; Barr et al., 2007; Qiu and Weeber, 2007). While the total 
levels of AMPA and NMDA receptors in the hippocampus were comparable between 
heterozygous reeler and wt littermates (Qiu et al., 2006c; Niu et al., 2008), a significant 
reduction in synaptic NMDA receptors has been described in the mutants as compared to wt 
(Niu et al., 2008), pointing again to the critical role of Reelin in glutamate receptor trafficking 
and composition. It is, however, unknown whether Reelin released from local hippocampal 
GABAergic interneurons is sufficient or whether the release from glutamatergic entorhinal 
cortex afferents is required for the modulation and regulation of these processes as well. 
Using preembedding immuno-electron microscopy, we have recently discovered Reelin 
immunoreactivity selectively associated with presynaptic glutamatergic terminals in the CA1 
stratum lacunosum moleculare, providing the first morphological evidence that Reelin indeed 
could rapidly activate postsynaptic NMDA receptors and thereby enhancing LTP at dendritic 
spines (Doehner, Knuesel unpublished observations). These findings are in agreement with 
previous ultrastructural findings of Reelin-immunoreactivity in small axon terminals and 
unmyelinated axons in the post-mortem human neocortex (Roberts et al., 2005), as well as in 
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smooth cisterns of the axon of Cajal-Retzius cells during development (Derer et al., 2001). 
These structures, named “axonal reelin reservoirs”, are associated with large extracellular 
space characteristic of the developing brain and are thought to represent local storage sites 
that allow the constitutive secretion of Reelin and potentially other factors into the 
extracellular matrix of the marginal zone (Derer et al., 2001). This neuronal activity-
independent release of Reelin has also been described for cultured cerebellar granule cells 
(Lacor et al., 2000; Sinagra et al., 2008), as well as hippocampal neurons (Sinagra et al., 2005; 
Groc et al., 2007; Campo et al., 2009), revealing a tight relationship between synthesis and 
release rate, that was independent of depolarization-regulated Ca2+-dependent exocytosis in 
vitro in a developmental context. It remains to be determined, however, whether a similar 
constitutive secretion is required for mature hippocampal neurons in vivo. Altogether, the 
current knowledge on Reelin, lipoprotein and glutamate receptors reveals the critical role of 
this signaling complex in controlling actin cytoskeleton and microtubule dynamics necessary 
for both the developing nervous system and synaptic plasticity and learning in the adult brain. 
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3. Implications of altered Reelin signaling for neurological and 
psychiatric diseases 
 
 
The prominent role for Reelin and its lipoprotein receptors in the control of synaptic functions 
and plasticity strongly supports the hypothesis that a dysfunctional Reelin-mediated signaling 
pathway plays a central role in neurological, neuropsychiatric and neurodegenerative 
disorders. Indeed, neuroanatomical studies have consistently reported Reelin abnormalities 
throughout the brain in patients with schizophrenia, bipolar disorder, autism, and major 
depression (Impagnatiello et al., 1998; Fatemi et al., 2000; Guidotti et al., 2000b; Costa et al., 
2001; Fatemi et al., 2001; Persico et al., 2001; Eastwood et al., 2003; Knable et al., 2004; 
Abdolmaleky et al., 2005). Various mechanisms may be operational in these neuropsychiatric 
disorders where Reelin production may be affected selectively in different brain areas by 
either altered genetic or epigenetic regulations causing differential expression levels in the 
developing or adult brain. The common theme emerging from the different reports strongly 
suggests that abnormalities in Reelin-mediated signaling not only increases the vulnerability 
to develop psychosis, it clearly promotes the development of moderate to severe cognitive 
dysfunctions. In addition to these psychiatric diseases, abnormalities in Reelin have been 
associated with some forms of human epilepsy, particularly mesial temporal lobe epilepsy 
(Haas et al., 2002) which is characterized by profound hippocampal sclerosis involving loss of 
pyramidal neurons, granule cell dispersion and reactive gliosis, as well as a significant 
reorganization of GABAA receptor subunit expression (Loup et al., 2006; Loup et al., 2009). 
Recently, Haas and colleagues provided experimental evidence that Reelin deficiency and 
displacement of mature neurons underlie the granule cell dispersion in the epileptic 
hippocampus (Heinrich et al., 2006; Muller et al., 2009). Moreover, the group of Bluemcke 
showed that this phenomenon was associated with increased reelin promoter methylation in 
the epileptic brain (Kobow et al., 2009), confirming that normal Reelin expression and 
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secretion is required to maintain neuroanatomical integrity in the adult brain. The following 
chapter focuses on the mechanisms of altered Reelin expression and processing during 
neurodevelopment and its impact on adult neuronal functions. 
 
Reelin in schizophrenia. Schizophrenia is a debilitating condition that affects approximately 
0.5% of the population worldwide (McGrath and Susser, 2009). The symptoms of this severe 
psychiatric disease include profound disturbances in mental functions, emotions, and behavior 
and usually render an individual unable to function in normal social situations. The onset of 
the disease usually occurs late in adolescence or early adulthood and is oftentimes associated 
with a precipitating, stressful life event. Current medications relieve some of the symptoms; 
however, most individuals continue to experience cognitive deficits throughout their life. 
Multiple lines of evidence suggest that schizophrenia has a neurodevelopmental origin, in 
which an initial, triggering event results in a robust set of neuroadaptations that significantly 
and progressively derange normal brain function, potentially long before the illness is 
clinically manifest (Weinberger, 1987; Harrison, 1997; Rapoport et al., 2005; Sun et al., 
2009). Several of these early neurodevelopmental disturbances including misplacements of 
neurons, especially in the interstitial white matter (IWM, Eastwood and Harrison, 2003), 
abnormal spine and synapse density (Kung et al., 1998; Arnold, 1999; Guidotti et al., 2000a; 
Kolomeets et al., 2007; Roberts et al., 2008) are dependent on Reelin-mediated signaling, 
suggesting that reduced Reelin levels during development may account for some of these 
abnormalities. Indeed, work from several groups provided evidence that Reelin mRNA and 
protein levels are significantly reduced in cortical layer I and IWM neurons, as well as 
interneurons in the prefrontal cortex, hippocampus, and cerebellum of schizophrenia patients, 
concurrently with a decrease in glutamic acid decarboxylase 67-kDa (GAD67, Impagnatiello 
et al., 1998; Fatemi et al., 2000; Guidotti et al., 2000b; Eastwood and Harrison, 2003; Knable 
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et al., 2004; Fatemi et al., 2005). Interestingly, the reduction in Reelin mRNA was also 
associated with altered expression pattern of several synaptic proteins in the same areas, 
including semaphorin 3A mRNA (negative correlation, (Eastwood and Harrison, 2003) as 
well as GAP-43, VGLUT1, and synaptophysin (all positively correlated, Eastwood and 
Harrison, 2006), supporting the view that Reelin deficiency may profoundly disturb 
synaptogenesis. These findings are also in line with the current view that schizophrenia is a 
heritable synaptic disorder involving multiple genes, all of which are known to have essential 
function in neuronal differentiation, survival, synaptogenesis, and apoptosis (Harrison and 
Weinberger, 2005; Harrison, 2007). One of the genes identified in a familial form of 
schizophrenia is disrupted-in-schizophrenia-1 (disc1, Blackwood et al., 2001; Miyoshi et al., 
2003). The gene product of disc1 is part of a microtubule motor complex, which is controlled 
by the Reelin and LIS1 signaling pathway  (Assadi et al., 2003) and mutations in this gene 
result in abnormal development of the cortex (Kamiya et al., 2005). However, other genetic 
association screenings have yielded inconclusive results, including the searches for 
associations between reelin polymorphisms and schizophrenia (Akahane et al., 2002; Chen et 
al., 2002; Goldberger et al., 2005; Huang and Chen, 2006; Persico et al., 2006; Shifman et al., 
2008; Gregorio et al., 2009). In contrast, a strong correlation between S-adenosyl-methionine 
(SAM), DNMT1, hypermethylation of the reelin promoter, and decreased Reelin expression 
in postmortem brains of subjects with schizophrenia has been reported (Costa et al., 2003; 
Veldic et al., 2004; Abdolmaleky et al., 2005; Grayson et al., 2005; Guidotti et al., 2007; 
Ruzicka et al., 2007; Tochigi et al., 2008). These results demonstrated that epigenetic 
derangements of the processes involved in DNA methylation, including the expression of 
DNMT and the production of the methyldonor SAM, results in aberrant silencing of reelin 
specifically in GABAergic interneurons but not in pyramidal neurons, potentially underlying 
the increased susceptibility of an individual to develop cognitive impairments associated with 
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psychiatric diseases. Recently, Dong and colleagues demonstrated a rapid demethylation of 
the reelin and GAD67 promoter following treatment of mice with valproate or MS-275, two 
structurally distinct inhibitors of histone deacetylase (HDAC, Dong et al., 2007). This effect 
was significantly potentiated in combination with the antipsychotics Clozapine and Sulpiride 
but not Haloperidol or Olanzapine (Dong et al., 2008), pointing to the therapeutic potential of 
HDAC inhibitors to facilitate DNA demethylation in terminally differentiated neurons in 
combination with antipsychotic medications in order to reverse transcriptional inactivation of 
the reelin gene. 
 
Neurodevelopmental animal models of schizophrenia. In addition to genetic and epigenetic 
factors, environmental risk factors have been implicated in the etiology of schizophrenia and 
other psychosis-related disorders. Among them, maternal infection during pregnancy is one of 
the currently most extensively studied risk factor in experimental schizophrenia research. This 
is based on a large body of epidemiological data that has provided compelling evidence for 
enhanced risk of schizophrenia following prenatal exposure to infection with various viral or 
bacterial pathogens, or genital and/or reproductive infections (Brown, 2006; Patterson, 2007; 
Boksa, 2008). Considering the diversity of infectious agents involved, it has been 
hypothesized that inflammation-induced expression of pro-inflammatory cytokines and other 
mediators of inflammation in the maternal host and eventually in the fetal brain may interfere 
with normal neurodevelopment, thereby predisposing the offspring to long-lasting changes 
ultimately leading to adult psychosis-related behavior in adulthood (Meyer et al., 2008a).    
Support for this assumption has been provided by numerous animal studies modeling 
prenatal immune activation in rats and mice which demonstrated a wide spectrum of 
behavioural, neuroanatomical, and neurochemical changes in adult offspring born to immune-
challenged mothers that are implicated in some of the most critical phenotypic symptoms of 
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schizophrenia. (for review, Sullivan et al., 2006). We have also established a 
neurodevelopmental schizophrenia model involving a prenatal immune challenge in mice 
using the viral mimic polyriboinosinic-polyribocytodilic acid (PolyI:C, Meyer et al., 2006; 
Meyer et al., 2008b), a synthetic analog of double-stranded RNA, shown to induce cytokine 
expression via Toll-like receptor 3 activation (Alexopoulou et al., 2001). The overall aim of 
the experiments was to test the hypothesis that developmental abnormalities induced by 
inflammatory cytokines during critical gestational windows can lead to dysregulation of 
multiple neurotransmitter systems that are involved in the typical neurochemical and 
pathophysiological processes related to schizophrenia in humans. To this end, we investigated 
the immunological, behavioural and neuroanatomical effects of this intense but time-limited 
in utero immune challenge in pregnant mouse dams on the exposed offspring from fetal, 
juvenile to adult stages. We provided first evidence that the time of maternal infection 
critically determines the patterns of the symptom clusters displayed by the offspring (Meyer et 
al., 2006): While inflammation during gestation day 9 (GD9) resulted in a behavioural profile 
mimicking certain aspects of psychotic symptoms, a late-gestational immune challenge 
resulted in a behavioural phenotype primarily characterized by cognitive impairments. These 
behavioural immunological findings were paralleled by characteristic changes in several 
neurotransmitter systems, including a preferential dopaminergic imbalance that was 
selectively associated with a immune challenge at GD9, whereas deficits in the glutamatergic 
neurotransmitter system were preferentially associated with a late-gestational (GD17) 
infection (Meyer et al., 2008b). We observed a robust, inflammation-induced reduction in 
Reelin-positive interneurons and substantial alterations in the GABAergic neurotransmitter 
system that emerged independently of the precise timing of the PolyI:C treatment (Nyffeler et 
al., 2006; Meyer et al., 2008b). Importantly, the schizophrenia-related behavioural and 
neurochemical abnormalities were not mediated by postnatal maternal rearing behaviour on 
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the offspring, but predominantly attributable to a prenatal immunological effect (Meyer et al., 
2008c). We further demonstrated that the fetal brain can directly contribute to the specific 
changes in inflammatory cytokine protein levels after late-gestational but not mid-gestational 
immune challenge (Meyer et al., 2006), suggesting a close correlation between acute 
immunological modulators and histopathological and neurochemical changes in the juvenile 
and adult offspring.   
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4. Functional link between Reelin, ApoE, APP,  
and Alzheimer’s disease  
 
 
Do Reelin and its lipoprotein receptors have a role in Alzheimer’s disease (AD)? If yes, is 
there an underlying neurodevelopmental cause for this severe neurodegenerative disease or is 
the progression of the cognitive decline and associated neuropathology associated with 
impaired Reelin-mediated signaling at adult synapses? The current experimental evidence 
does not demonstrate causality yet, but an increasing number of studies have been 
investigating the molecular mechanisms by which Reelin, its receptors and downstream 
signaling proteins may contribute to the etiology of this progressive neurodegenerative 
disease. The following chapter summarizes the current knowledge on the etiology and 
neuropathology of the disease, as well as recent findings on the potential implications of 
abnormal ApoE and Reelin signaling in AD. 
 
ApoE and Alzheimer’s disease. AD is the most common type of age-related dementia, 
characterized by a progressive cognitive decline and severe neurodegeneration (Savla and 
Palmer, 2005). Neuropathological hallmarks include neurofibrillary tangles, consisting of 
hyperphosphorylated Tau (Grundke-Iqbal et al., 1986) and senile plaques, composed of 
amyloid-β (Aβ) peptides (Glenner and Wong, 1984); the amyloidogenic cleavage product of 
the amyloid precursor protein (APP) that results from its cleavage by β- and γ-secretases 
(Estus et al., 1992; Haass et al., 1992). Non-amyloidogenic cleavage by sequential cleavage 
through α- and γ-secretase results in the production and release of a large N-terminal 
extracellular fragment and smaller, membrane-bound C-terminal fragments with putative 
neuroprotective and transcriptional functions (Furukawa et al., 1996; Gao and Pimplikar, 
2001; von Rotz et al., 2004). Recently, the team of Tessier-Lavigne discovered an additional 
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disease-modifying, N-terminal fragment of APP that acts as ligand of the death receptor 6 
(DR6, a member of the tumor necrosis factor receptor superfamily). This fragment is 
produced by β-secretase plus an additional, as yet unidentified, protease and has been shown 
to induce Caspase-6-mediated axonal degeneration upon growth factor withdrawal (Nikolaev 
et al., 2009, Figure 4). These findings point to a critical role of APP in early brain 
development that is required to prune excess axon growth; which is in line with recent 
evidence showing that full-length APP is required for proper migration of neuronal precursors 
into the cortical plate during the neurodevelopment (Young-Pearse et al., 2007). Interestingly, 
the authors also provide evidence that overexpression of Dab1 was able to partially rescue the 
phenotype of APP knockdown, indicating that Dab1 acts downstream of APP for this function 
in cortical plate entry. Altogether, these recent results suggest that abnormal 
neurodegeneration associated with AD might be due to inappropriate activation or 
reactivation of a developmental pathway in the aged brain. 
While the rare early-onset forms of the disease are caused by mutations in app, 
presenilin 1 and 2 genes, all favoring amyloidogenic APP processing and accelerating the 
production of Aβ peptides (Goate et al., 1991; Levy-Lahad et al., 1995; Rogaev et al., 1995; 
Sherrington et al., 1995), no apparent familial segregation is evident for late-onset AD, which 
affects the vast majority of patients.  
The mechanisms that alter Aβ production in these patients are largely unknown. It is 
assumed that combinations of several genetic and non-genetic risk factors have a substantial 
impact on disease predisposition (Bertram and Tanzi, 2008). Among the more than 500 genes 
associated with late-onset AD, only apolipoprotein E (apoE) ε4 has been proved to 
consistently influence disease risk, age at onset, amyloid burden and cognitive performance 
(Corder et al., 1993; Schmechel et al., 1993; Bertram and Tanzi, 2008). The apoE gene 
encodes a 34-kDa protein that is expressed throughout the brain. It is synthesized and secreted 
  19 
by astrocytes and microglia and involved in the regulation of the lipid metabolism (Boyles et 
al., 1985; Xu et al., 2006; Riddell et al., 2008; Zhao et al., 2009). It exists in three allelic 
variants in humans: ApoE ε2, ε3 and ε4 that differ in two amino acids at positions 112 and 
158 (Arg or Cys). This structural polymorphism influences the confirmation of ApoE and 
modulates the quality and stability of the protein’s binding to lipoprotein particles, cellular 
receptors and Aβ peptides, thereby creating conditions for isoform-specific effects on the 
development of a number of chronic diseases (Karim and Burns, 2003; Dergunov, 2006; 
Urosevic and Martins, 2008; Belinson and Michaelson, 2009; Bookheimer and Burggren, 
2009).  The common denominator for peripheral and CNS lipid disorders is ApoE ε4, which 
has been associated with poor clearance and recycling of lipoprotein particles carrying 
cholesterol and Aβ peptides. This inability to maintain lipid homoeostasis not only increases 
the risk for atherosclerosis and cardiovascular diseases, it also promotes the accumulation of 
soluble Aβ in brain tissue and CSF as well as an increased deposition of fibrillary Aβ in brain 
parenchyma and walls of small blood vessels (Urosevic and Martins, 2008). Two recent 
studies provided novel molecular mechanism for the impaired Aβ clearance that may explain 
the strong isoform-dependent effects of ApoE in determining the genetic risk for AD. Riddel 
and colleagues provided experimental evidence that the levels of secreted ApoE ε4 and 
cholesterol measured in the culture medium from human astrocytoma or primary astrocytes 
expressing ε3/4 was significantly lower than ε3 due to enhanced degradation and reduced 
half-life of newly synthesized ε4 (Riddell et al., 2008). In addition to the lower expression 
levels of ApoE and putative reduced Aβ clearance, ε4 carriers may additionally suffer from 
reduced Aβ degradation by circulating bone marrow-derived microglia as compared to ε3 or 
ε2 carriers as suggested by the work of Zhao and colleagues (Zhao et al., 2009). 
Interestingly, an age-specific epigenetic drift associated with unusual methylation 
patters in late-onset AD patients has been recently identified, supporting a potential role for 
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epigenetic modulations in AD etiology (Wang et al., 2008). Strikingly, apoE showed the 
largest inter-individual variance in DNA methylation in a ε-haplotype-specific manner in AD 
patients. These findings fit with other recent observations which revealed that adverse 
environmental influences including exposure to toxic substances can result in elevated levels 
of APP and Aβ peptides in the adult and aged brain, potentially due to abnormal epigenetic 
imprinting (Wu et al., 2008; Zawia et al., 2009). It is conceivable, therefore, that the abnormal 
methylation of apoE alleles differentially affect their expression and localization, which in 
turn may impair their binding to neuronal receptors that is required for proper cholesterol 
metabolism, cellular signaling, and clearance of Aβ. 
 
Reelin, APP and Alzheimer’s disease. The effect of ApoE on Aβ clearance is achieved 
through endocytosis mediated by several members of the family of lipoprotein receptors 
(Herz and Chen, 2006). As described above, two of these receptors, ApoER2 and VLDLR, 
also serve as receptors for Reelin. The findings that ApoEε3 and ε4 inhibit Reelin receptor 
binding more efficiently than ε2 (D'Arcangelo et al., 1999) provides further support for a 
functional convergence between Reelin and ApoE-mediated signaling at synaptic sites which 
not only modulates NMDA-receptor mediated neurotransmission and synaptic plasticity, but 
appears to directly affect Αβ- and Tau-related neuropathology. In the following, I will 
summarize the links between Reelin and its signaling pathway with the main hallmarks of AD 
pathology, including our own recent findings of the first evidence of altered Reelin-mediated 
signaling in the etiology of AD.  
 The first association of Reelin with AD features has been provided by the observation 
that reeler and apoer2/vldlr double-knockout mice show hyperphosphorylated Tau protein 
(Hiesberger et al., 1999), the basic structural component of paired helical filaments and 
neurofibrillary tangles. The groups of Herz and Mitsuda showed that signaling pathways 
  21 
involved in the regulation of Tau phosphorylation include the activity of both, GSK-3β and 
CDK5, likely in parallel rather than sequential manner (Beffert et al., 2002; Ohkubo et al., 
2003; Beffert et al., 2004). Together with our own findings of a pronounced decline in the 
expression levels of Reelin in the hippocampal formation of old wild-type mice, rats, and non-
human primates (Knuesel et al., 2009), these results demonstrate that an age-related decline in 
Reelin-mediated signaling may indeed trigger alterations in downstream kinase activity that 
result in abnormal phosphorylation of Tau and neurofibrillary tangles formation. This in turn 
is expected to destabilize the microtubule network and axonal transport, ultimately resulting 
in neuronal degeneration and cell death.  
 No coherent picture has emerged yet regarding putative changes in Reelin expression in 
human AD patients. Riedel and colleagues reported only marginal changes in Reelin levels in 
Cajal-Retzius cells in the entorhinal cortex of AD subjects as compared to normal aging 
(Riedel et al., 2003). However, the Cajal-Retzius cells seemed to be selectively affected by 
the formation of paired helical filaments, pointing to subtle changes in Reelin levels that are 
sufficient to trigger abnormal Tau phosphorylation. Baloyannis (2005) and Chin et al. (2007) 
on the other hand reported a dramatic decline in the number of Cajal-Retzius cells and layer II 
pyramidal cells in the entorhinal cortex, respectively, in early cases of AD. Although a more 
comprehensive evaluation of Reelin levels in Cajal-Retzius cells as well as GABAergic 
interneurons in the hippocampal formation is needed, the current findings, including the 
recently described AD-related polymorphisms in the RELN locus (Seripa et al., 2008) point to 
a critical role of Reelin and its associated signaling cascade in AD-associated neuropathology.  
 In line with this hypothesis, recent evidence from Javier Saez-Valero’s group suggests a 
prominent link between abnormal Reelin levels and AD pathogenesis. Using a biochemical 
approach, they reported altered glycosylation and increased levels of the N-terminal 180-kDa 
Reelin fragment in the CSF and frontal cortex brain extracts of AD patients as compared to 
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non-demented control subjects (Saez-Valero et al., 2003; Botella-Lopez et al., 2006). 
Interestingly, full-length Reelin mRNA was also elevated in the frontal cortex but this did not 
translate into increased levels of full-length or the 310-kDa forms in AD compared to control, 
strongly supporting - beside a putative compensatory transcriptional change – prominent 
alterations in proteolytic processing of the full-length protein in the diseased stage. A recent 
study showed that the N-terminal fragment can also be generated within the endosome after 
internalization of the full-length form (Hibi and Hattori, 2009), pointing to the possibility that 
in AD patients the endosomal recycling and re-secretion of this fragment into the extracellular 
space is also significantly affected. Our own findings of a striking aging-associated 
accumulation of Reelin in oligomeric amyloid-β plaques in several species (Knuesel et al., 
2009) offer an alternative explanation: N-terminal fragments might preferentially oligomerize 
and aggregate in the neuropil. The load of these Reelin-positive plaques in combination with 
the reduction in Reelin-expressing interneurons significantly correlated with episodic-like 
memory impairments. Moreover, we found that the course and magnitude of the plaque load 
was modulated by exacerbated inflammatory responses and genetic mutations favoring the 
production of Aβ peptides (Knuesel et al., 2009). Using high-resolution confocal microscopy, 
we found that Reelin was selectively associated but not co-localized with fibrillary amyloid-β 
species. Oligomeric Aβ plaques, on the other hand, showed a very high degree of co-
localization with Reelin (Doehner et al., 2009), confirming and extending previous findings 
that revealed Reelin and ApoER2-immunoreactivity associated with neuritic components of 
Aβ plaques in AD mice (Wirths et al., 2001; Motoi et al., 2004). Our results not only support 
the critical role of Reelin in modulating normal NMDA receptor-mediated neurotransmission 
and synaptic plasticity, but also highlighting the relationship between Reelin, APP processing 
and Aβ deposition. 
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 The molecular basis for this link has been provided by the work of Tom Curran’s and 
Joachim Herz’s groups. They showed that the intracellular adaptor Dab1 in addition to 
ApoER2 also binds to the cytoplasmic NPXY motif of APP (Trommsdorff et al., 1998; 
Homayouni et al., 1999). This interaction appears to directly affect the trafficking and 
processing of ApoER2 and APP. Hoe and Rebeck’s group tested this in vitro and found that 
overexpression of Dab1 resulted in increased cell surface localization of APP and ApoER2 in 
COS7 cells, as well as increased α-secretase and decreased β-cleavage of APP (Hoe et al., 
2006a). Others confirmed in HEK cells the Dab1-related increase in APP surface localization 
and α-secretase cleavage but found also an increase in β-secretase cleavage (Parisiadou and 
Efthimiopoulos, 2007). Interestingly, Reelin significantly increased the Dab1-APP and Dab1-
ApoER2 interactions, as shown by co-immunoprecipitation and immunocytochemistry 
(Morimura et al., 2005; Hoe et al., 2006a). Moreover, the presence of Reelin in the culture 
media also increased the cleavage of APP and significantly decreased Aβ in the presence of 
Dab1. Furthermore, Hoe and Rebeck provided first evidence of a direct interaction between 
the central Reelin fragment and the E1 extracellular domain of APP; an interaction that 
appears to be necessary for proper neurite outgrowth both in vitro and in vivo (Hoe et al., 
2009). Based on this data, it is conceivable that reduced Reelin-dependent signaling may be a 
critical upstream signal at synapses able to shift APP processing from non-amyloidogenic to 
amyloidogenic forms in vivo.  
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5. Reelin-mediated signaling in normal and pathological aging: A 
novel link between development, inflammation and degeneration 
 
 
The major advances in terms of understanding the pathology underlying many neurological 
disorders has been the realization that inflammation is not only involved in acute CNS 
conditions, such as stroke and traumatic injury, but that it is also a central factor in chronic 
and neurodegenerative conditions such as AD or Parkinson’s disease (PD). However, despite 
the overwhelming number of studies linking neurotoxic inflammatory responses to AD 
pathogenesis, very little information is available on early, potentially causative inflammatory 
processes that are effective during development, adulthood, or aging and pre-plaque 
deposition stages that might possess stronger disease-inducing and -modifying potential than 
the amyloid plaque-associated inflammatory responses. In line with this view, classical 
neurodegenerative diseases like AD and PD are still thought to have an adult onset, i.e. the 
beginning of degenerative changes in a previously normal functioning brain. However, it is 
plausible that disturbances of normal development may significantly increase the brains’ 
susceptibility to neurodegenerative processes and other disease-specific changes as it has been 
shown for neurological disorders with a developmental origin, such as epilepsy, schizophrenia 
or autism. In view of the critical role of Reelin during development and adult neuronal 
functioning in concert with APP, the general theme of this part of the review therefore centers 
around the impact of prenatal inflammation-induced as well as aging-associated reduction in 
Reelin-dependent signaling in the etiology and pathophysiology of late-onset AD in general 
and cerebral amyloidosis in particular. 
 
The role of inflammatory modulators in Alzheimer’s disease. Postmortem brain studies 
consistently reveal strong accumulations of activated microglia and astrocytes in the vicinity 
of senile amyloid-β plaques and neuronal lesions, accompanied by the abundant presence of 
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inflammatory mediators, such as cytokines, chemokines, prostaglandins, complement 
activation components, and oxygen radicals (McGeer and McGeer, 2002). It has become 
apparent that these molecules, once considered to be in the exclusive domain of circulating 
leukocytes and peripheral immune organs, are locally produced in the brain; most of them by 
the activated glial cells, but many of them also by neurons (McGeer and McGeer, 2002). This 
evolutionary conserved host-defense mechanism is based on the recognition of foreign 
molecular patterns and hence involved in neuroprotection through phagocytosis of cytotoxic 
substances. Numerous human postmortem studies have shown that the initial pathological 
stages in the hippocampus and entorhinal cortex in AD include, beside the activation of 
inflammatory mediators, a pronounced up-regulation of cell cycle and cell adhesions proteins 
(Parachikova et al., 2007), hypothesized to reflect an initial regenerative response of neurons 
to the presence of diffuse Aβ plaques and oligomeric or protofibrillic forms of Aβ peptides 
(Hoozemans et al., 2006; Salminen et al., 2009). Later stages are then characterized by the 
widespread deposition of amyloid-β plaques and neurofibrillary tangles with their focal 
complement activation and accumulation of activated glial cells. Under these chronic 
conditions, the efficiency of the so-called innate immune system appears to fluctuate and it 
has been suggested that unwanted potentiation of pro-inflammatory responses could turn the 
beneficial innate immunity into a negative driving force in AD pathogenesis by inducing 
autotoxicity (McGeer and McGeer, 2002; Wyss-Coray, 2006; Salminen et al., 2009). Clearly, 
more information is needed to support an adverse, and potentially early misregulated innate 
immunity defense, however, mouse models with genetic manipulations of inflammatory 
pathways indicate that dysfunctional immune modulators may be indeed causally involved in 
AD neuropathology (Wyss-Coray, 2006). Support for this hypothesis has been provided by 
clinical evidence for a critical role of inflammation in AD pathology. Several epidemiological 
studies demonstrated that individuals who regularly take non-steroidal anti-inflammatory 
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drugs (NSAIDs) for conditions such as rheumatoid arthritis have a considerably reduced risk 
of developing AD (McGeer et al., 1996; Stewart et al., 1997). Although first clinical trials 
with anti-inflammatory NSAIDs did not show significant improvement in progressive 
dementia (Walker and Lue, 2007), better designed classes of COX1-inhibitors that efficiently 
cross the blood-brain-barrier are expected to support the epidemiological evidence in favor of 
a strong protective effect of NSAID in AD (McGeer and McGeer, 2002).  
  
Inflammatory cytokines in AD. As mentioned above, activated microglia and astrocytes in 
the AD brain emit several pro-inflammatory signals, with the cytokines apparently playing a 
paramount role in the deleterious processes linked to AD (Jones et al., 2009). Cytokines are a 
heterogeneous group of small molecules that act in autocrine and paracrine fashion. They 
encompass several subfamilies, including interleukins (ILs), interferons, tumor necrosis 
factors (TNFs), growth factors, colony-stimulating factors, and chemokines (Mrak and 
Griffin, 2005). They have in common the participation in inflammatory reactions, typically 
acting context-specifically and in combination thereby exerting either pro- or anti-
inflammatory action.  
 We have shown that in utero exposure to PolyI:C results in abnormal expression levels 
of IL1β, IL6, IL10, and TNFα in the embryos (Meyer et al., 2006). Moreover, we have 
preliminary evidence that the levels of IL1α and β, IL6, and TNFα remain high in adult and 
aged hippocampus but not neocortex of PolyI:C- versus NaCl-exposed mice, a phenomenon 
that was accompanied by an significant increase in the density of ThioflavinS-positive murine 
amyloid-β plaques (Madhusudan, Breu, Doehner, Knuesel, unpublished data). Interestingly, 
the cytokines found to be elevated in aged PolyI:C-exposed subjects are the most significantly 
up-regulated in AD, all being prominently associated with the characteristic neuropathological 
hallmarks of AD (Sheng et al., 1995; Mrak and Griffin, 2005), suggesting that our findings of 
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long-lasting alterations in the innate immune system might be causally involved in abnormal 
APP processing and Aβ peptide production in PolyI:C-exposed mice. Support for this 
hypothesis is provided by several studies showing direct effects of exogenously applied IL1 
on APP processing and Aβ deposition (Sheng et al., 1996), as well as Tau phosphorylation via 
p38/MAPK signaling (Sheng et al., 2000; Sheng et al., 2001; Griffin et al., 2006). Similar 
findings have been reported for IL6, recently shown to directly modulate Tau phosphorylation 
via the cdk5/p35 pathway in hippocampal neurons (Quintanilla et al., 2004). TNFα has also 
been shown to directly induce the production of Aβ peptides in vitro (Yamamoto et al., 2007) 
and mediate amyloid-induced toxicity both in vitro and in vivo (Li et al., 2004; Medeiros et 
al., 2007). Moreover, inhibition of TNF receptor signaling in transgenic AD mice results in 
decreased Aβ plaque formation (He et al., 2007). In humans, elevation of TNF receptors, 
enhanced β-secretase activity, and Aβ levels in the CSF appear to represent significant 
predictors of conversion from mild cognitive impairment to AD (Buchhave et al., 2008), 
suggesting that elevation of TNFα and other inflammatory cytokines are involved in the early 
prodromal phase of AD.  
 
Prenatal brain inflammation and its impact on adult neuronal functioning. In addition to 
regulating inflammatory responses induced by neurodegenerative processes, cytokines are 
also important modulators of neuronal activity, differentiation, and survival during 
neurodevelopment. Exposure to cytokines during different stages of development both in cell 
culture systems and in vivo can inhibit neuritic or dendritic outgrowth and branching as well 
as causing hypomyelination and abnormalities in cell migration (Biber et al., 2002). 
Moreover, recent data showed that the balance between the excitatory and inhibitory synaptic 
activity can be progressively disturbed for extended periods of time following treatment with 
cytokines during synaptogenesis (Biber et al., 2002; Brask et al., 2004; Hellstrom et al., 2005; 
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Serantes et al., 2006). It is, thus, conceivable that overexposure to cytokines during early brain 
development affecting cell migration and neuronal differentiation can lead to multiple 
morphological and neurochemical defects which result in disturbances of homeostatic 
neuronal network activity in the adult brain. The observation that these defects are frequently 
accompanied by profound behavioral abnormalities has lead to the hypothesis that some of the 
clinical symptoms of neuropsychiatric disorders might have a neurodevelopmental origin 
(Harrison, 1999). Our own investigations (Doehner et al., 2009; Knuesel et al., 2009; 
Madhusudan et al., 2009) provide first support for a comparable relationship for 
neurodegenerative diseases like AD. We present first data on the link between maternal 
infection during pregnancy, abnormal Reelin expression and acceleration of AD-like 
neuropathology in aged wild-type mice. These novel findings fit very well with a recent but 
widely accepted paradigm that normal aging is accompanied by a low-grade chronic up-
regulation of certain inflammatory response. This phenomenon has been termed 
“inflammaging” and refers to an over-active innate immunity by cells of the mononuclear 
phagocyte lineage in elderly people (Giunta et al., 2008). Importantly, enhanced 
overproduction of pro-inflammatory modulators is found in both healthy and pathological 
aging. However, healthy elderly individuals generally demonstrate potent anti-inflammatory 
responses that likely counteract the adverse immunity. On the other hand, a portion of 
individuals may shift from a normal/subclinical to an abnormal/disease-associated state due to 
persistent inflammation which may promote AD neuropathology and chronic degeneration 
(Sarkar and Fisher, 2006). Genetic factors like polymorphisms in promoter and untranslated 
regions that favor increased expression of pro- or anti-inflammatory cytokines have been 
shown to significantly correlate with enhanced and reduced risk of AD, respectively (Sarkar 
and Fisher, 2006; Giunta et al., 2008). It is conceivable that non-genetic factors such as 
adverse short- and long-term effects of a prenatal infection are equally capable of shifting the 
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balance between tissue damaging and healing towards a chronic and systemic pro-
inflammatory state.  
 We have recently started a comprehensive investigation using biochemical, 
immunohistochemical, and ultrastructural approaches to examine the expression pattern of 
Reelin during aging and its relationship to cognitive performance. We contrasted the effect of 
a prenatal infection, genetic factors including AD-causing mutations, with conditions 
occurring during normal aging on Reelin expression levels, plaque deposition and 
neurodegenerative processes. Our data provided first evidence that aging across species from 
mouse, rat, to non-human primates, and humans is accompanied by a reduction in Reelin 
expression levels and number of Reelin-positive GABAergic interneurons (Knuesel et al., 
2009, IK unpublished data). Unexpectedly, we detected that Reelin itself is able to form 
aggregates in the form of amyloid-like plaques during normal aging. Both neuropathological 
alterations significantly correlated with hippocampus-dependent episodic-like memory 
deficits. We found that healthy and cognitively normal subjects were able to sufficiently clear 
and degrade these deposits, whereas cognitively impaired aged mice failed to do so. A 
prenatal immune challenge during late gestation or overexpression of AD-causing gene 
products resulted in earlier, higher and much more persistent levels of Reelin-positive 
deposits. These results show for the first time that prenatal exposure to infection during late 
embryonic developmental stages is not only an important factor in the segregation of certain 
behavioural symptom clusters with relevance for neuropsychiatric disorders but does also 
represent a critical driving force of aging-related neuropathological processes.  
 We further developed a new immunohistochemical protocol involving a stringent 
protease pretreatment which markedly enhanced Reelin-immunoreactivity and allowed 
specific detection of several murine proteolytic APP fragments in plaques in the aged 
hippocampus (Doehner et al., 2009). The same treatment in APP knockout mice did not reveal 
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any comparable staining pattern, confirming the specificity of the immunoreactivity. 
Moreover, our investigations using this adapted immunohistochemical protocol allowed the 
detection of fibrillary Aβ deposits as seen in human, indicating that similar aging-related 
pathophysiological changes occur in rodents. Our ultrastructural investigations confirmed the 
presence of Reelin in extracellular space, somata of interneurons in young and aged wild-type 
mice. In aged mice, both Reelin- and amyloid-β-immunoreactivity were detected in 
extracellular, spherical deposits; likely representing small intermediates or fragments of 
amyloid fibrils, confirming our immunohistochemical data and pointing to the usefulness of 
non-transgenic animals to investigate early molecular mechanisms that underlie the shift from 
normal to pathological forms of aging.  
 Support for this statement is also provided by our investigation that focused on the 
hypothesis that early accumulations of extracellular protein deposits in the projection areas of 
subcortical neurons could induce retrograde neuronal degeneration. Considering the highly 
consistent finding of aging-related Reelin plaque deposition in target areas of cholinergic 
neurons, such as the hippocampus, entorhinal and piriform cortex, we reasoned that Reelin 
plaques could impair the integrity of axonal terminals, potentially resulting in degeneration of 
basal forebrain projection neurons (Madhusudan et al., 2009). We also investigated the impact 
of Reelin plaque deposition on GABAergic projection neurons in the basal forebrain, since 
they selectively innervate the GABAergic Reelin-expressing interneurons in the hippocampus 
(Pascual et al., 2004). We found that the age-related neuropathological changes in 
hippocampus, entorhinal and piriform cortices of aged wild type mice are accompanied by 
abnormal axonal varicosities and altered expression profiles of calcium-binding proteins in 
plaque-dense areas. Moreover, we report a significant reduction in the number of 
parvalbumin-positive GABAergic projection neurons in basal forebrain areas including 
medial septum (MS), ventral and horizontal diagonal Band of Broca (VDB/HDB), and 
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substantia innominata (SI) compared to young subjects. A significant reduction in the number 
of choline acetyltransferase-positive cholinergic projection neurons was evident in the 
HDB/SI area but not in the MS of aged compared to young wild type mice. No Reelin-
deposits were found in these basal forebrain regions, suggesting that the loss of projection 
neurons was not due to adverse effects of local protein deposition and plaque formation. 
Altogether, our findings suggest that the elevated Reelin plaque load in the projection areas of 
afferent subcortical GABAergic and cholinergic neurons including hippocampus, entorhinal 
and piriform cortex affects the axonal integrity and survival of these neurons, potentially also 
contributing to the cognitive impairments observed in aged wild type mice. 
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6. CONCLUSIONS AND PERSPECTIVES 
 
 
Inflammation-induced disturbances in the Reelin–mediated signaling pathway: A point 
of convergence between chronic psychiatric and neurodegenerative disorders? 
The findings presented in this review suggest a critical and potential convergent role of 
dysfunctional Reelin-mediated signaling in schizophrenia and AD.  
 1) We provide first evidence in a mouse model of schizophrenia that developmental 
abnormalities induced by inflammatory cytokines results in a downregulation of Reelin 
expression which is accompanied by dysregulated communication between multiple 
neurotransmitter systems, involving GABAergic, glutamatergic, and dopaminergic 
neurotransmission that mimic typical neurochemical and pathophysiological processes related 
to schizophrenia in humans. Reelin not only plays a fundamental role during development by 
controlling neuronal migration, it is also capable of directly influence NMDA receptor-
mediated neurotransmission by regulating its subunit composition and AMPA receptor 
insertion during synapse formation and strengthening in the developing and adult brain, 
respectively. Our findings therefore suggest that abnormal Reelin-mediated signaling during 
critical phases of embryonic development has a profound impact on neuronal connectivity and 
this potentially underlies the severe cognitive and affective dysfunctions associated with 
schizophrenia in human patients.  
 2) We show for the first time that aging across species is accompanied by a reduction in 
Reelin expression, accompanied by a highly selective layer-specific accumulation of Reelin-
positive amyloid-like plaques. Comprehensive ultrastructural and immunohistochemical 
characterizations indicate that Reelin, likely by self-aggregating into abnormal oligomeric or 
protofibrillary deposits during aging, is able to induce degenerative axonal varicosities in 
afferent basal forebrain projection neurons that selectively terminate in plaque-dense areas 
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within the hippocampal formation. Moreover, we provide evidence that a prenatal infection 
and its associated long-term misbalanced expression levels of inflammatory cytokines results 
in a much earlier and more persistent Reelin plaque deposition, allowing the detection of 
oligomeric murine amyloid-β species within, and fibrillary amyloid-β aggregates surrounding 
the Reelin-positive plaques, respectively. Altogether, the findings obtained so far suggest that 
infection- or aging-induced reduction in Reelin-dependent signaling plays a proximal role in 
synaptic dysfunction associated with abnormal brain amyloid-β production and cerebral 
amyloidosis, potentially by creating a precursor or seeding condition for senile amyloid-β 
plaque formation. 
 
Co-morbidity in schizophrenia and AD. Our findings add important new data on current 
concepts on overlapping molecular pathogenic pathways in schizophrenia and AD. So far, 
commonalities between the two brain disorders have been largely restricted to cognitive and 
psychiatric symptoms. They are based on the one hand on clinical studies reporting 
progressive cognitive impairments and a higher incidence of AD pathology in 
institutionalized patients with schizophrenia as compared to normal elderly (Buhl and Bojsen-
Moller, 1988; Soustek, 1989; Prohovnik et al., 1993; Glantz et al., 2006), and on the other 
hand on typical psychiatric manifestations, such as psychosis (e.g. delusions and 
hallucinations), disruptive behaviours (e.g. psychomotor agitation and physical aggression) in 
AD patients, especially during later stages with more rapid rates of cognitive decline and 
progression of the disease (Devanand et al., 1997; Hollingworth et al., 2006; Meeks et al., 
2006; Reeves and Brister, 2008). Postmortem neuropathological investigations, however, 
have provided conflicting results regarding the occurrence of AD hallmarks in schizophrenia 
patients (Dwork et al., 1998; Powchik et al., 1998; Harrison, 1999; Niizato et al., 2001; Religa 
et al., 2003; Glantz et al., 2006). Interestingly, studies performed before the era of 
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neuroleptics reported in general higher incidences of AD in schizophrenia patients compared 
to the patients dying during the neuroleptic era (Oken and McGeer, 1996). Beside a potential 
neuroprotective effect of some of the neuroleptics, such as Haloperidol and Droperidol, 
shown to inhibit proteolytic processing of APP (DesJarlais et al., 1990; Higaki et al., 1997; 
Arnold et al., 1998), as well as the neurogenesis-promoting effect of other neuroleptics, such 
as Clozapine (Maeda et al., 2007), improvements in the neuropsychological assessment as 
well as modern imaging techniques have certainly contributed to the better diagnosis and can 
at least partially explain the conflicting results of AD-schizophrenia co-morbidity. On the 
other hand, it is becoming evident that the density of senile, fibrillary amyloid-β plaques does 
not correlate well with the cognitive performance; rather, impairments in cognition as well as 
plaque-associated neurotoxicity have been associated with diffusible amyloid-β oligomers 
(Lambert et al., 1998; Walsh et al., 2002) or intraneuronal accumulations of amyloid-β 
peptides (Lee et al., 1998; Kienlen-Campard et al., 2002), shown to disrupt normal neuronal 
synaptic transmission (Knobloch et al., 2007). In line with a role of soluble amyloid-β species 
underlying cognitive impairments, our findings in the prenatal infection model of 
schizophrenia, which revealed a significant acceleration of oligomeric amyloid-β plaque 
deposition in wild-type mice as compared to controls (Knuesel et al., 2009), indicate that 
reduced Reelin-mediated signaling may result in abnormal protein deposition disrupting 
neuronal functioning and cognition in both schizophrenia and AD patients. It will be 
important, therefore, to investigate using better and more sensitive tools the occurrence of 
Reelin- and amyloid-β-positive oligomeric plaques in postmortem tissue from schizophrenia 
patients. 
  
Reelin signaling and molecular pathways in schizophrenia and AD. Novel and unexpected 
roles for Reelin have recently emerged: We understand now in detail how this highly 
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conserved and evolutionarily ancient protein controls neuronal migration and cortical 
lamination during development. Interestingly, the same molecular signaling pathway is used 
in the adult brain where Reelin and its receptors are pivotal regulators of NMDA receptor 
function, underlying synaptic plasticity and learning and memory. One of the most important 
question that has arisen from these novel insights concern the molecular mechanisms by 
which Reelin, APP/Aβ, ApoE, and the ApoE2, VLDL receptors cooperate at the synapse to 
synergistically regulate the NMDA receptor and thereby control neurotransmission in the 
context of a healthy and diseased brain. In the following, I propose how the Reelin-mediated 
signaling pathway could be involved in the pathogenesis of schizophrenia and AD by 
differentially affecting NMDA receptor-mediated neurotransmission. In the normal, healthy 
brain, Reelin by binding to the ApoER2/VLDL receptor induces the phosphorylation of Dab1 
through Src/Fyn non-receptor tyrosine kinases. This in turn facilitates the phosphorylation of 
the NR2A and 2B subunit of the NMDA receptors, potentiating calcium influx and facilitating 
the insertion of GluR1-containing AMPA receptors. Reelin-induced augmentation of Ca2+ 
entry through NMDA receptors increases also phosphorylation and nuclear translocation of 
the transcription factor cAMP-response element binding protein (CREB), involved in the 
regulation of spine formation (Segal, 2001); all adaptations necessary for normal synaptic 
plasticity and learning and memory. In the schizophrenic brain, Reelin deficiency (induced 
through genetic, epigenetic, or non-genetic factors), may result in early developmental 
abnormalities involving neuronal malpositioning, altered neuronal connectivity and 
synapse/spine density, impaired developmental switch from NR2B to NR2A, and sustained 
levels of silent synapses. This glutamatergic hypofunction may secondarily affect other 
neurotransmitters such as the dopaminergic system in the frontal cortex but is not expected to 
induce any major neurodegenerative processes. However, reduced Reelin-mediated signaling 
may through the APP-Dab1 interaction alter the proteolytic processing of APP, thereby 
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facilitating the production of amyloidogenic Aβ peptide that can further block NMDA 
receptor-mediated neurotransmission. In addition, reduced Reelin levels may not only 
facilitate its own aggregation in the form of oligomer and protofibrils which impair the 
integrity of cholinergic and GABAergic projection neurons, it might also induce the 
formation of neurofibrillary tangles through over activation of GSK3β and Cdk5, a 
neuropathological hallmark frequently seen in schizophrenic patients. All these 
pathophysiological changes are expected to result in further aggravation of cognitive 
performance in schizophrenia patients. A similar scenario is conceivable in the normal aging 
brain. Reelin expression levels is expected to gradually decline, associated with an increased 
accumulation of Reelin-positive plaques in the hippocampal formation and cortical areas. 
While elderly persons with an intact immune system and/or elevated levels of anti-
inflammatory modulators will be able to successfully clear and degrade the extracellular 
deposits; persons with genetic predispositions for amyloidogenic APP processing or high 
expression of pro-inflammatory modulators, or epigenetic changes further reducing Reelin 
expression levels, may fail to remove the deposits. These, in turn, by providing a seeding site 
for other aggregation-prone peptides and proteins, will promote and aggravate plaque 
pathology and associated inflammatory reactions. Sustained and chronic overexpression of 
certain pro-inflammatory cytokines such as IL1, IL6 and TNFα are expected to promote 
neurodegeneration and result in a worsening of the disease state. In parallel, reduced Reelin-
mediated signaling, expected to promote the formation of neurofibrillary tangles through 
GSK3β and Cdk5-mediated hyperphosphorylation, and the loss of Reelin-expressing 
GABAergic interneurons may result in further imbalances between excitation and inhibition, 
resulting in progressive neuronal degeneration and cell death. 
Finally, factors able to shift abnormalities in the Reelin-mediated signaling pathway 
towards neuropsychiatric or neurodegenerative symptoms clearly involve genetic factors and 
  37 
Mendelian mutations implicated in schizophrenia and AD, respectively. For schizophrenia, 
these involve the DISC1, NRG1, or COMT genes, all of which appear to converge at synaptic 
sites, indirectly or directly involved in modulating NMDA receptor-mediated 
neurotransmission. For AD, known dominant mutations in the APP or presenilin genes all 
favoring protein aggregation, may further facilitate Reelin aggregation (Botella-Lopez et al., 
2009), thereby promoting impairments in glutamatergic neurotransmission. Our data obtained 
from the PolyI:C model of schizophrenia also provides first evidence that the gestational 
window during which adverse environmental factors like viral or bacterial infections and its 
associated increase in inflammatory cytokines interfere with normal neurodevelopmental 
processes, critically determines the symptom clusters in the exposed offspring: While 
exposure to prenatal infection during mid gestation induced behavioural and neurochemical 
alterations related to schizophrenia in our mouse model; in utero infection during late 
gestation favored cognitive impairments and neuropathology related to AD. I speculate that 
developmental inflammation during early/mid gestation may play an important role in 
initiating abnormal neuronal migration and positioning of neurons, which may primarily 
affect neuronal connectivity in the adult offspring. Due to the immature immune system of the 
embryo at this stage, long-term alterations in critical pro-inflammatory immune modulators 
are expected to be only moderately elevated as compared to later stages of embryonic 
development. On the other hand, developmental inflammation during late gestation will be 
expected to affect predominantly neurite outgrowth and synaptogenesis, accompanied by 
sustained and long-term alterations in the expression of immune modulators thanks to the 
more mature immune system of the infection-exposed embryo. This may – despite the 
likelihood that the density of Reelin-expressing neurons are comparable, increase the 
susceptibility of the brain to further exposure to drugs, toxins and otherwise normal processes 
of aging, potentially resulting in late-onset Alzheimer’s disease.  
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In conclusion, from the evidence presented in this review, I propose that dysfunctional Reelin-
mediated signaling is a common feature of both neuropsychiatric and neurodegenerative 
diseases. I hypothesize that the progression from normal aging to late-onset AD could result 
from early misregulations of pro-inflammatory cytokines, resulting in immediate neuronal 
loss of Reelin-expressing interneurons, facilitation of protein aggregation and impairments in 
amyloid plaque clearance and proteolytical degradation in adulthood, accompanied by chronic 
inflammation. Activation of microglia by pro-inflammatory cytokines, apoptosis of astrocytes 
and neurons that lead to a reduction in synthesis and release of neuroprotective factors likely 
adds further to the neurodegenerative disease state of AD. I further suggest that a differential 
immune modulator profile able to prevent progressive neurodegeneration is characteristic for 
schizophrenia and aging. It is plausible that a gradual decline in Reelin-mediated signaling as 
seen during normal aging and a developmental insult inducing early dysfunction in Reelin and 
its associated signaling pathway would induce similar neurochemical and neuropathological 
processes. Thus, the findings presented in this review suggest that schizophrenia can indeed 
be seen and described as a form of accelerated aging or “dementia praecox” as first described 
by Emil Kraepelin in 1899 (Kraepelin, 1991). 
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7. FIGURE LEGENDS 
 
 
Figure 1. Protein structure of Reelin. The reelin gene encodes a 12-kb mRNA which is 
translated into a 3,461 amino acid (aa) protein with a relative molecular mass of about 450 
kDa. The glycosylated N-terminus shares 25% identity with F-spondin. The central sequence 
consists of eight repeats each of which is composed of 350-390 aa and contains a central 
EGF-like motif. This is followed by a highly charged C-terminus which appears to be 
essential for the secretion of the protein. Recent evidence suggest also an involvement of the 
C-terminus in the activation of downstream signaling events, potentially mediated by a co-
receptor. Reelin is processed proteolytically by so far unidentified proteinases at two sites to 
produce a total of five different fragments, named after the position and number of repeats 
and ranging from 80-370 kDa in size. 
 
Figure 2. Reelin-mediated signaling during development. Binding of multimeric Reelin to 
VLDLR and ApoER2 induces their clustering and phosphorylation of the cytoplasmic adapter 
protein disabled 1 (Dab1) by the Src family tyrosine (SFKs) kinases Fyn and Src. Dab1 is 
initially phosphorylated on two (Tyr185, Tyr198) sites which seem to be required to permit 
transphosphorylation of adjacent Dab1 molecules at all sites (Tyr185, Tyr198, Tyr220, 
Tyr232). This leads to the recruitment and activation of additional activated non-receptor 
tyrosine kinases allowing the activation of a cytosolic kinase cascade, beginning with 
Phosphatidylinositol-3-kinase (PI3K), Akt/PKB and mTor, and ending with the inhibition of 
Glycogen synthase kinase 3β (GSK3β), one of the main kinases that phosphorylates the 
microtubule-stabilizing protein Tau. While phosphorylated Dab1(Y185,Y198) preferentially 
activates the PI3-kinase/Akt pathway, phospho-Dab1(Y220,Y232) recruits Crk/CrkL-C3G 
complexes which in turn stimulate Rap1. The central Reelin domain also directly interacts 
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with the E1 extracellular domain of APP; an interaction that appears to be necessary for 
proper neurite outgrowth both in vitro and in vivo. Recruitmnet of ubiquitin ligases to 
phosphorylated Dab1 results in ubiquitination of the protein, likely mediating the 
phosphorylation-dependent endocytosis of the entire Reelin signaling complex. With Reelin 
being targeted to the lysosome and Dab1 being degraded by the proteasome, the signal is 
terminated and the receptors recycle back to the membrane. 
 
Figure 3. Reelin modulates synaptic plasticity and learning and memory. Dab1 binding site 
and exon 19 of ApoER2 are necessary for the Reelin-mediated increase in synaptic plasticity 
to allow the coupling of the Reelin receptor and the activated Dab1–Src/Fyn complex to the 
NR2A and NR2B subunit of the NMDA receptor for its subsequent tyrosine phosphorylation 
and Ca2+ entry in the postsynaptic density, PSD (Beffert et al., 2005). Prolonged presence of 
Reelin at synaptic sites also modulates AMPA receptor-mediated responses, associated with 
an increased receptor number in the PSD (Qiu et al., 2006b) and reduction in the number of 
silent synapses that facilitated the developmental switch from NR2B to NR2A (Qiu and 
Weeber, 2007). Reelin-induced augmentation of Ca2+ entry through NMDA receptors is likely 
also involved in the regulation of downstream signaling cascades involved in learning and 
memory (Chen et al., 2005). These data fit with the observations that in the absence of Reelin 
or the Reelin receptors, neurons exhibit stunted dendritic growth, a reduction in dendritic 
branches and significantly fewer spines (Del Rio et al., 1997; Borrell et al., 1999; 
Trommsdorff et al., 1999; Niu et al., 2004; Borrell et al., 2007; Qiu and Weeber, 2007; Niu et 
al., 2008).  
 
Figure 4. Amyloid precursor protein (APP) processing. Senile plaques, one of the 
neuropathological hallmarks of Alzheimer’s disease are mainly composed of amyloid-β (Aβ) 
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peptides, the amyloidogenic cleavage product of APP that results from sequential cleavage by 
β- and γ-secretases. Non-amyloidogenic cleavage through α- and γ-secretases results in the 
production and release of a large N-terminal extracellular fragment (sAPPα) and smaller, C-
terminal fragments (APP intracellular domain, AICD) with putative neuroprotective and 
transcriptional functions. Recently, an additional putative disease-modifying, N-terminal 
fragment of APP that acts as ligand of the death receptor 6 (DR6) has been discovered. This 
fragment, which is released from β-secretase-cleaved sAPPβ fragments by a yet unidentified 
protease upon growth factor withdrawal, is required to prune excess axonal growth during 
early neuronal development via Caspase-6-mediated axonal degeneration. In AD, abnormal 
neurodegeneration might be due to inappropriate activation or reactivation of a developmental 
pathway in the aged brain, potentially involving abnormal interaction between Reelin and the 
N-terminal domain of APP. 
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